Amylyx Pharmaceuticals, Inc.

AMLXNASDAQHealthcare● Active

$12.88

$-0.44(-3.28%)

Market Cap$1.1B

P/E Ratio—

52W High$18.605

52W Low$4.76

Avg Volume1.1M

Open$13.51

Beta-0.16

Net Income Financials Revenue

Amylyx Pharmaceuticals, Inc. (AMLX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

AMLX · net income · updated Jun 8, 2026

Core profitability metrics

AMLX · net income · margin · TTM · CAGR

Net income was −$144.7M for FY2025 (fiscal year ending 2025-12-31), up 52.0% year-over-year. Net profit margin was —. Based on available data, Amylyx Pharmaceuticals, Inc. has been profitable since at least 2023.

FY2025 Net Income−$144.7M▲ +52.0% YoY

Trailing 12M (TTM)−$150.1Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change+52.0%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2023

▸ FMP /income-statement · Annual · AMLX net income history · AMLX profit margin

Annual net income data

AMLX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$144.7M▲ +52.0%—$0

FY2024Loss−$301.7M▼ 712.4%-345.4%$87.4M

FY2023★ First Profit$49.3M▲ +124.8%12.9%$380.8M

FY2022Loss−$198.4M▼ 125.6%-892.4%$22.2M

FY2021Loss−$87.9M▼ 108.0%—$0

Net income vs peers (Healthcare)

AMLX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Amylyx Pharmaceuticals, Inc.YOU

AMLX

−$144.7M+52.0%—

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Amylyx Pharmaceuticals, Inc. (AMLX) reported net income of −$144.7M for FY2025 (fiscal year ending 2025-12-31), up 52.0% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Based on available data, Amylyx Pharmaceuticals, Inc. has been profitable since at least 2023. Net income reached a peak of $49.3M in FY2023. Data available for 7 fiscal years.

Amylyx Pharmaceuticals, Inc.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Amylyx Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from AMLX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

AMLX net income · 4 questions

Amylyx Pharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $144.7M for FY2025.

is AMLX profitabledoes AMLX make a profitAMLX profitabilityAMLX profitable company

▸ Source: FMP /income-statement · GAAP · Amylyx Pharmaceuticals, Inc. · Amylyx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026